BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Most End-Stage Heart Disease Patients Show Significant Improvement After Adult Stem Cell Treatment; Interim Clinical Data From TheraVitae Study Presented At AHA Scientific Sessions


11/16/2005 2:59:34 PM

DALLAS--(BUSINESS WIRE)--Nov. 16, 2005--TheraVitae, an international biotechnology company and the producer of VesCell(TM) adult stem cell therapy for heart disease, today presented interim clinical data showing significant improvement in patients suffering from severe angina pectoris six months after they received the company's autologous adult stem cell therapy. Unlike most clinical trials currently underway, VesCell uses adult stem cells derived from a patient's own blood rather than his or her bone marrow. Prof. Alex Battler, MD, Director of Cardiology at the Rabin Medical Center in Israel and TheraVitae's chief medical officer, presented the results at the American Heart Association's Scientific Session here. In addition to showing that VesCell has a high safety profile the results demonstrate that: -- 93% of patients reported an increased ability to perform physical exercise. -- 62% showed improvement in treadmill exercise capacity. -- 73% of patients showed an improvement in perfusion defect of the ischemic region, assessed by SPECT. The study, evaluating the safety and efficacy of intracoronary administration of VesCell to patients suffering from severe angina pectoris, is being conducted in conjunction with Her Majesty's Cardiac Center at Siriraj Medical Hospital in Bangkok, Thailand.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->